{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T04:30:12Z","timestamp":1772253012939,"version":"3.50.1"},"reference-count":73,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.6772-25","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:09:33Z","timestamp":1771884573000},"source":"Crossref","is-referenced-by-count":0,"title":["Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics"],"prefix":"10.2169","author":[{"given":"Ryotaro","family":"Ikeguchi","sequence":"first","affiliation":[{"name":"Department of Neurology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women's Medical University, Japan"},{"name":"Department of Medical Safety, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Todo","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Women's Medical University, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112, 2004.","DOI":"10.1016\/S0140-6736(04)17551-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202: 473-477, 2005.","DOI":"10.1084\/jem.20050304"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Takai Y, Kuroda H, Misu T, et al. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord 49: 102750, 2021.","DOI":"10.1016\/j.msard.2021.102750"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Misu T, Fujihara K, Kakita A, et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224-1234, 2007.","DOI":"10.1093\/brain\/awm047"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Wingerchuk DM, Lucchinetti CF. Neuromyelitis Optica Spectrum Disorder. N Engl J Med 387: 631-639, 2022.","DOI":"10.1056\/NEJMra1904655"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Fujihara K, Bennett JL, de Seze J, et al. Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm 7: e841, 2020.","DOI":"10.1212\/NXI.0000000000000841"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Mitsdoerffer M, Kuchroo V, Korn T. Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci 1283: 57-66, 2013.","DOI":"10.1111\/nyas.12118"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Hou MM, Li YF, He LL, et al. Proportions of Th17 cells and Th17-related cytokines in neuromyelitis optica spectrum disorders patients: A meta-analysis. Int Immunopharmacol 75: 105793, 2019.","DOI":"10.1016\/j.intimp.2019.105793"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ikeguchi R, Shimizu Y, Kondo A, et al. Melanoma Cell Adhesion Molecule Expressing Helper T Cells in CNS Inflammatory Demyelinating Diseases. Neurol Neuroimmunol Neuroinflamm 8: e1069, 2021.","DOI":"10.1212\/NXI.0000000000001069"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Uzawa A, Mori M, Sato Y, et al. CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse. J Neurol Neurosurg Psychiatry 83: 339-344, 2012.","DOI":"10.1136\/jnnp.2011.241760"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Uzawa A, Mori M, Arai K, et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler 16: 1443-1452, 2010.","DOI":"10.1177\/1352458510379247"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kaneko K, Sato DK, Nakashima I, et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. J Neurol Neurosurg Psychiatry 89: 927-936, 2018.","DOI":"10.1136\/jnnp-2018-317969"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Agasing AM, Wu Q, Khatri B, et al. Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nat Commun 11: 2856, 2020.","DOI":"10.1038\/s41467-020-16625-7"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 72: 53-64, 2012.","DOI":"10.1002\/ana.23651"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Holm\u00f8y T, H\u00f8glund RA, Illes Z, et al. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J Neurol 268: 4522-4537, 2021.","DOI":"10.1007\/s00415-020-10235-5"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bennett JL, O'Connor KC, Bar-Or A, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2: e104, 2015.","DOI":"10.1212\/NXI.0000000000000104"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Chihara N, Aranami T, Sato W, et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci USA 108: 3701-3706, 2011.","DOI":"10.1073\/pnas.1017385108"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Chihara N, Aranami T, Oki S, et al. Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica. PLoS One 8: e83036, 2013.","DOI":"10.1371\/journal.pone.0083036"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Kowarik MC, Astling D, Gasperi C, et al. CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol 4: 369-380, 2017.","DOI":"10.1002\/acn3.418"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Nishigori R, Hamatani M, Yoshitomi H, et al. CD21lo B-cell subsets are recruited to the central nervous system in acute neuromyelitis optica. Brain 148: 2995-3010, 2025.","DOI":"10.1093\/brain\/awaf086"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kinoshita M, Nakatsuji Y, Kimura T, et al. Neuromyelitis optica: Passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun 386: 623-627, 2009.","DOI":"10.1016\/j.bbrc.2009.06.085"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Saadoun S, Waters P, Bell BA, et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133: 349-361, 2010.","DOI":"10.1093\/brain\/awp309"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Duan T, Smith AJ, Verkman AS. Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity. Acta Neuropathol Commun 7: 112, 2019.","DOI":"10.1186\/s40478-019-0766-7"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol 11: 535-544, 2012.","DOI":"10.1016\/S1474-4422(12)70133-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol 27: 485-517, 2009.","DOI":"10.1146\/annurev.immunol.021908.132710"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Takeshita Y, Obermeier B, Cotleur AC, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 4: e311, 2017.","DOI":"10.1212\/NXI.0000000000000311"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Takeshita Y, Fujikawa S, Serizawa K, et al. New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD. Neurol Neuroimmunol Neuroinflamm 8: e1076, 2021.","DOI":"10.1212\/NXI.0000000000001076"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Watanabe M, Isobe N, Niino M, et al. Prevalence of, and Disability Due to, Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder in Japan by the Fifth Nationwide Survey. Neurology 103: e209992, 2024.","DOI":"10.1212\/WNL.0000000000209992"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ikeguchi R, Shimizu Y, Suzuki S, et al. Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature. Clin Neurol Neurosurg 125: 217-221, 2014.","DOI":"10.1016\/j.clineuro.2014.07.036"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Akaishi T, Nakashima I, Takahashi T, et al. Neuromyelitis optica spectrum disorders with unevenly clustered attack occurrence. Neurol Neuroimmunol Neuroinflamm 7: e640, 2020.","DOI":"10.1212\/NXI.0000000000000640"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85: 177-189, 2015.","DOI":"10.1212\/WNL.0000000000001729"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kojima M, Oji S, Tanaka S, et al. Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody. Mult Scler Relat Disord 39: 101907, 2020.","DOI":"10.1016\/j.msard.2019.101907"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Luo D, Wei R, Tian X, et al. Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies. Mult Scler Relat Disord 46: 102484, 2020.","DOI":"10.1016\/j.msard.2020.102484"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Li X, Tian D, Liu L, et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord 39: 101916, 2020.","DOI":"10.1016\/j.msard.2020.102325"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Lin J, Xue B, Zhu R, et al. Intravenous immunoglobulin as the rescue treatment in NMOSD patients. Neurol Sci 42: 3857-3863, 2021.","DOI":"10.1007\/s10072-021-05079-4"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Vieira GD, Boldrini VO, Mader S, et al. Ravulizumab and other complement inhibitors for the treatment of autoimmune disorders. Mult Scler Relat Disord 95: 106311, 2025.","DOI":"10.1016\/j.msard.2025.106311"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381: 614-625, 2019.","DOI":"10.1056\/NEJMoa1900866"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Okusa S, Takizawa T, Imai S, et al. Serious bacterial infections associated with eculizumab: a pharmacovigilance study. Intern Med 63: 1061-1066, 2024.","DOI":"10.2169\/internalmedicine.1893-23"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 381: 2114-2124, 2019.","DOI":"10.1056\/NEJMoa1901747"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Ikeguchi R, Shimizu Y, Kuroda R, Todo K. Satralizumab treatment in neuromyelitis optica spectrum disorder: effects on relapse, pain, and other medications used: a retrospective chart review. Mult Scler Relat Disord 103: 106706, 2025.","DOI":"10.1016\/j.msard.2025.106706"},{"key":"41","doi-asserted-by":"publisher","unstructured":"41. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial. Lancet 394: 1352-1363, 2019.","DOI":"10.1016\/S0140-6736(19)31817-3"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Flanagan EP, Levy M, Katz E, et al. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study. Mult Scler Relat Disord 57: 103352, 2022.","DOI":"10.1016\/j.msard.2021.103352"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Tan CS, Koralnik IJ. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol 9: 425-437, 2010.","DOI":"10.1016\/S1474-4422(10)70040-5"},{"key":"44","doi-asserted-by":"publisher","unstructured":"44. Cree BA, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64: 1270-1272, 2005.","DOI":"10.1212\/01.WNL.0000159399.81861.D5"},{"key":"45","doi-asserted-by":"publisher","unstructured":"45. Yang CS, Yang L, Li T, et al. Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81: 710-713, 2013.","DOI":"10.1212\/WNL.0b013e3182a1aac7"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Kim SH, Jeong IH, Hyun JW, et al. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72: 989-995, 2015.","DOI":"10.1001\/jamaneurol.2015.1276"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Tahara M, Oeda T, Okada K, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 19: 298-306, 2020.","DOI":"10.1016\/S1474-4422(20)30066-1"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Pittock SJ, Barnett M, Bennett JL, et al. Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. Ann Neurol 93: 1053-1068, 2023.","DOI":"10.1002\/ana.26626"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Clardy SL, Pittock SJ, Aktas O, et al. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder. Neurol Ther 13: 535-548, 2024.","DOI":"10.1007\/s40120-024-00597-7"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. John N, Lim A, Ram Sunthar S, et al. Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis. J Neurol 272: 563, 2025.","DOI":"10.1007\/s00415-025-13279-7"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Yamazaki N, Misu T, Matsumoto Y, et al. The real-world impact of biologics for NMOSD: a retrospective single-center study compared with natural course and conventional treatments in Japanese. Mult Scler Relat Disord 92: 106176, 2024.","DOI":"10.1016\/j.msard.2024.106176"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Ringelstein M, Asseyer S, Lindenblatt G, et al.; German Neuromyelitis Optica Study Group (NEMOS). Eculizumab use in neuromyelitis optica spectrum disorders: routine clinical care data from a European cohort. Neurology 103: e209888, 2024.","DOI":"10.1212\/WNL.0000000000209888"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. H\u00e4u\u00dfler V, Trebst C, Engels D, et al. Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD. J Neurol Neurosurg Psychiatry 96: 582-592, 2025.","DOI":"10.1136\/jnnp-2024-334764"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Javed Z, Du M, Rensel M, et al. Real world effectiveness and tolerability of novel monoclonal antibodies and rituximab for NMOSD. Ann Clin Transl Neurol 12: 2152-2157, 2025.","DOI":"10.1002\/acn3.70160"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Jacob A, Mahmoud A, Saab RR, et al. Post marketing real-world experience of ravulizumab in NMOSD. Mult Scler Relat Disord 104: 106747, 2025.","DOI":"10.1016\/j.msard.2025.106747"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Lin LT, Lin HA, Lin SF. Real-world investigation of satralizumab in patients with neuromyelitis optica spectrum disease. Ann Clin Transl Neurol 0: 1-11, 2025.","DOI":"10.1002\/acn3.70246"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. Matsuyoshi A, Shinoda K, Takeuchi H, et al. The real-world experience of biologics for neuromyelitis optica spectrum disorders as first-line and switched therapy. J Neuroimmunol 410: 578799, 2026.","DOI":"10.1016\/j.jneuroim.2025.578799"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. Fujimoto T, Maeda Y. Eculizumab use throughout pregnancy in two patients with aquaporin-4-positive neuromyelitis optica spectrum disorder.. Clin Exp Neuroimmunol 15: 126-129, 2024.","DOI":"10.1111\/cen3.12784"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. Guerra T, Paolicelli D, Iaffaldano P. Eculizumab treatment during pregnancy in a patient with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder: a case report. Mult Scler 31: 615-617, 2025.","DOI":"10.1177\/13524585241283648"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. Miyasaka N, Miura O, Kawaguchi T, et al.; Working Group for Pregnancy in PNH, The Japan PNH Study Group. Pregnancy outcomes of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: a Japanese experience and updated review. Int J Hematol 103: 703-712, 2016.","DOI":"10.1007\/s12185-016-1946-x"},{"key":"61","unstructured":"61. Sarno L, Tufano A, Maruotti GM, et al. Eculizumab in pregnancy: a narrative overview. J Nephrol 31: 673-683, 2018."},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. Yoshida T, Watanabe O, Nomura M, et al. Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report. Front Neurol 14: 1322412, 2023.","DOI":"10.3389\/fneur.2023.1322412"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. Nakashima S, Hao A, Uchio N, et al. Successful childbirth during satralizumab treatment in neuromyelitis optica spectrum disorder. Cureus 16: e55010, 2024.","DOI":"10.7759\/cureus.55010"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. Yaguchi H, Miyagawa S, Nakada R, Yamamoto S, Goto R, Funaki S. Safe Childbirth in a Patient with Neuromyelitis Optica Spectrum Disorder Treated with Satralizumab. Intern Med 2025. Online ahead of print.","DOI":"10.2169\/internalmedicine.5870-25"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. Miranda-Acu\u00f1a J, Rivas-Rodr\u00edguez E, Levy M, et al. Rituximab during pregnancy in neuromyelitis optica: a case report. Neurol Neuroimmunol Neuroinflamm 6: e542, 2019.","DOI":"10.1212\/NXI.0000000000000542"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. Munger KC, Samkoff LM. Initiation of rituximab therapy for new onset neuromyelitis optica spectrum disorder during pregnancy: a case report. Mult Scler Relat Disord 37: 101442, 2020.","DOI":"10.1016\/j.msard.2019.101442"},{"key":"67","unstructured":"67. Ahadi MS, Sahraian MA, Shaygannejad V, et al. Pregnancy outcome in patients with neuromyelitis optica spectrum disorder treated with rituximab: a case-series study. Caspian J Intern Med 12: S491-S494, 2021."},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. Jacob A, Mahmoud A, Eldweik L, Mubashir A. Transplacental transfer of ravulizumab in a pregnant woman with neuromyelitis optica: a case report. BMJ Neurol Open 7: e001286, 2025.","DOI":"10.1136\/bmjno-2025-001286"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. Shimizu Y, Ikeguchi R, Fujihara K, Todo K. Progress in the Management of Pregnancy in Patients with Neuromyelitis Optica Spectrum Disorder. Ther Adv Neurol Disord 18: 1-15, 2025.","DOI":"10.1177\/17562864251384504"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. Wu Y, Geraldes R, Jury\u0144czyk M, et al. Double antibody-negative neuromyelitis optica spectrum disorder. Mult Scler 29: 1353-1362, 2023.","DOI":"10.1177\/13524585231199819"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. Fragoso DC, Salles LMOP, Pereira SLA, et al. AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging? Arq Neuropsiquiatr 81: 533-543, 2023.","DOI":"10.1055\/s-0043-1768669"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. Lotlikar RS, Nair SS, Prasad A, et al. A comparative study on clinico-radiological profile, treatment responses and outcomes of double seronegative NMOSD compared to AQP4-IgG positive NMOSD, and MOGAD. Mult Scler Relat Disord 103: 106669, 2025.","DOI":"10.1016\/j.msard.2025.106669"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. Marignier R, Pittock SJ, Paul F, et al.; N-MOmentum study investigators. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 57: 103356, 2022.","DOI":"10.1016\/j.msard.2021.103356"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_6772-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:42:21Z","timestamp":1772250141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_6772-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":73,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6772-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"6772-25"}}